BG103930A - Фармацевтични състави съдържащи елетриптан хемисулфат и кофеин - Google Patents

Фармацевтични състави съдържащи елетриптан хемисулфат и кофеин

Info

Publication number
BG103930A
BG103930A BG103930A BG10393099A BG103930A BG 103930 A BG103930 A BG 103930A BG 103930 A BG103930 A BG 103930A BG 10393099 A BG10393099 A BG 10393099A BG 103930 A BG103930 A BG 103930A
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical compositions
containing pharmaceutical
eletriptan hemisulphate
caffeine containing
caffeine
Prior art date
Application number
BG103930A
Other languages
English (en)
Inventor
Valerie Harding
Anne Billotte
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103930A publication Critical patent/BG103930A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до воден фармацевтичен състав, съдържащ от 5 до 200 mg/ml елетриптан хемисулфат и от 0,5 до 2,0% тегло/обем кофеин.
BG103930A 1997-07-03 1999-11-30 Фармацевтични състави съдържащи елетриптан хемисулфат и кофеин BG103930A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (1)

Publication Number Publication Date
BG103930A true BG103930A (bg) 2000-07-31

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103930A BG103930A (bg) 1997-07-03 1999-11-30 Фармацевтични състави съдържащи елетриптан хемисулфат и кофеин

Country Status (31)

Country Link
US (1) US6166025A (bg)
EP (1) EP0999841B1 (bg)
JP (1) JP3350061B2 (bg)
CN (1) CN1145486C (bg)
AT (1) ATE206921T1 (bg)
AU (1) AU724728B2 (bg)
BG (1) BG103930A (bg)
BR (1) BR9810658A (bg)
CA (1) CA2292673C (bg)
DE (1) DE69802097T2 (bg)
DK (1) DK0999841T3 (bg)
DZ (1) DZ2549A1 (bg)
EA (1) EA002174B1 (bg)
ES (1) ES2163291T3 (bg)
HK (1) HK1029282A1 (bg)
HR (1) HRP990416B1 (bg)
HU (1) HUP0004468A3 (bg)
ID (1) ID24528A (bg)
IL (1) IL133206A0 (bg)
IS (1) IS5283A (bg)
MA (1) MA26518A1 (bg)
NO (1) NO312993B1 (bg)
NZ (1) NZ501419A (bg)
OA (1) OA11227A (bg)
PL (1) PL337803A1 (bg)
PT (1) PT999841E (bg)
SI (1) SI0999841T1 (bg)
SK (1) SK284462B6 (bg)
TR (1) TR199903332T2 (bg)
UY (1) UY25078A1 (bg)
WO (1) WO1999001135A1 (bg)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU4799700A (en) * 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20080286388A1 (en) * 2004-10-22 2008-11-20 Shin-Jen Shiao Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2009504767A (ja) 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP2012036167A (ja) * 2010-07-16 2012-02-23 Taisho Pharmaceutical Co Ltd 内服液剤
US8915245B2 (en) * 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
WO2014143453A1 (en) * 2013-03-15 2014-09-18 Henkin Robert I Phosphodiesterase inhibitor treatment
EP3488889A1 (en) 2013-08-08 2019-05-29 Vapotherm, Inc. Respiratory therapy condensation adaptor
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
EP0999841B1 (en) 2001-10-17
PT999841E (pt) 2002-02-28
ATE206921T1 (de) 2001-11-15
WO1999001135A1 (en) 1999-01-14
CN1145486C (zh) 2004-04-14
ID24528A (id) 2000-07-20
DE69802097T2 (de) 2002-03-14
AU8856998A (en) 1999-01-25
EA199901100A1 (ru) 2000-08-28
SK182899A3 (en) 2000-09-12
AU724728B2 (en) 2000-09-28
EA002174B1 (ru) 2002-02-28
CN1261279A (zh) 2000-07-26
OA11227A (en) 2003-07-18
DZ2549A1 (fr) 2003-02-08
CA2292673A1 (en) 1999-01-14
ES2163291T3 (es) 2002-01-16
JP2000516262A (ja) 2000-12-05
IL133206A0 (en) 2001-03-19
NO995887L (no) 2000-03-02
IS5283A (is) 1999-11-30
NZ501419A (en) 2000-09-29
HRP990416A2 (en) 2000-04-30
DE69802097D1 (de) 2001-11-22
HUP0004468A3 (en) 2004-07-28
TR199903332T2 (xx) 2000-09-21
SK284462B6 (sk) 2005-04-01
NO312993B1 (no) 2002-07-29
EP0999841A1 (en) 2000-05-17
HK1029282A1 (en) 2001-03-30
SI0999841T1 (bg) 2001-12-31
US6166025A (en) 2000-12-26
JP3350061B2 (ja) 2002-11-25
BR9810658A (pt) 2000-10-03
HRP990416B1 (en) 2002-04-30
HUP0004468A2 (hu) 2001-10-28
UY25078A1 (es) 2000-12-29
DK0999841T3 (da) 2001-11-19
PL337803A1 (en) 2000-09-11
CA2292673C (en) 2003-04-22
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01

Similar Documents

Publication Publication Date Title
BG103930A (bg) Фармацевтични състави съдържащи елетриптан хемисулфат и кофеин
AP9901534A0 (en) Pharmaceutical formulations.
HUP9903174A2 (hu) Koenzim Q-10-et tartalmazó gyógyászati készítmény
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
BG102172A (bg) Фармацевтични препарати за получаване на аерозоли, свободни от пропелант
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
CA2348086A1 (en) Controlled-release pharmaceutical formulations
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
CA2270177A1 (en) Transdermal administration of ment
BG102589A (bg) 3-азетидинилалкилпиперидини или - пиролидини катотахикининови антагонисти
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
CA2152771A1 (en) 7-o-ethers of taxane derivatives
WO1999006388A8 (en) Pharmaceutical compounds isolated from aristolochia taliscana
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG103306A (bg) Течни алендронатни състави
BG106151A (bg) Фармацевтичен комплекс
TW218011B (bg)
BG106534A (bg) Разтвор за перорално приложение, съдържащ галантамин и подсладител
BG102638A (bg) Таблети с високо съдържание на фамцикловир
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.
AR013165A1 (es) Composiciones farmaceuticas que contienen eletriptan hemisulfato